Articles by Airama Albisa - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Airama Albisa

Manufacturing Process Development for an Epidermal Growth Factor-Based Cancer Vaccine

By incorporating disposable technologies and an improved purification scheme, scale-up and validation problems were resolved.
Oct 2, 2008

The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapy targeting the epidermal growth factor (EGF). The vaccine is composed of a chemical conjugate of EGF and a carrier protein (rP64k), designed to trigger an anti-EGF antibody response. The results of studies of molecular characterization, immunogenic activity, and clinical data are presented here.

ADVERTISEMENT

ADVERTISEMENT

Click here